Literature DB >> 1960545

Neurological disease associated with anticardiolipin antibodies in patients without systemic lupus erythematosus: clinical and immunological features.

A M Chancellor1, R E Cull, D C Kilpatrick, C P Warlow.   

Abstract

Anticardiolipin antibodies (aCL), one of a group of antiphospholipid antibodies which include the lupus anticoagulant (LA), may occur in association with systemic lupus erythematosus (SLE) and are less commonly detected in other diseases. We retrospectively reviewed the clinical and immunological features of 39 consecutive patients with abnormal aCL identified by one laboratory, to examine the spectrum of neurological disease in those patients without SLE. Fourteen patients in this category are described, 6 of whom did not have evidence of LA. All but 1 presented with neurological symptoms. Stroke and migraine dominated the clinical presentation, but many patients had features to suggest the presence of a hypercoagulable state. This study lends support to the concept of a primary antiphospholipid syndrome.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1960545     DOI: 10.1007/bf00319860

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  49 in total

1.  Fluorescent antibody methods.

Authors:  A H COONS
Journal:  Gen Cytochem Methods       Date:  1958

2.  Anti-phospholipid antibodies and ischaemic optic neuropathy.

Authors:  M T Watts; M Greaves; L G Clearkin; R G Malia; S M Cooper
Journal:  Lancet       Date:  1990-03-10       Impact factor: 79.321

3.  Neuropsychiatric lupus erythematosus, cerebral infarctions, and anticardiolipin antibodies.

Authors:  R A Fields; W L Sibbitt; H Toubbeh; A D Bankhurst
Journal:  Ann Rheum Dis       Date:  1990-02       Impact factor: 19.103

4.  Epitopes in medicine: the example of the lupus anticoagulant.

Authors:  J D Bessman
Journal:  JAMA       Date:  1988 Jan 22-29       Impact factor: 56.272

5.  Anticardiolipin antibodies in autoimmune thrombocytopenic purpura.

Authors:  E N Harris; A E Gharavi; U Hegde; G Derue; S H Morgan; H Englert; J K Chan; R A Asherson; G R Hughes
Journal:  Br J Haematol       Date:  1985-02       Impact factor: 6.998

6.  Migrainous phenomena in systemic lupus erythematosus.

Authors:  K D Brandt; S Lessell
Journal:  Arthritis Rheum       Date:  1978 Jan-Feb

7.  Anti-cardiolipin antibodies in neurological disorders: cross-reaction with anti-single stranded DNA activity.

Authors:  C B Colaço; G K Scadding; S Lockhart
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

8.  Etiology, prognosis, and hemostatic function after cerebral infarction in young adults.

Authors:  A M Chancellor; G L Glasgow; P A Ockelford; A Johns; J Smith
Journal:  Stroke       Date:  1989-04       Impact factor: 7.914

9.  Embolic stroke complicating systemic lupus erythematosus.

Authors:  P B Gorelick; M S Rusinowitz; M Tiku; L W McDonald; L Robbins
Journal:  Arch Neurol       Date:  1985-08

10.  A sensitive test demonstrating lupus anticoagulant and its behavioural patterns.

Authors:  T Exner; K A Rickard; H Kronenberg
Journal:  Br J Haematol       Date:  1978-09       Impact factor: 6.998

View more
  3 in total

Review 1.  Primary antiphospholipid antibody syndrome and cerebral ischemia: report on acute intervention in two cases and literature review with emphasis on therapeutic options.

Authors:  S Braune; R Siekmann; P Vaith; C H Lücking
Journal:  Rheumatol Int       Date:  1993       Impact factor: 2.631

2.  Primary antiphospholipid syndrome (PAPS) and isolated partial seizures in adolescence. A case report.

Authors:  R Spreafico; S Binelli; M G Bruzzone; D Croci; V Rumi; L Angelini
Journal:  Ital J Neurol Sci       Date:  1994-09

Review 3.  Anticardiolipin antibodies in the polymyalgia rheumatica-temporal arteritis syndromes.

Authors:  R M McLean; T P Greco
Journal:  Clin Rheumatol       Date:  1995-03       Impact factor: 2.980

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.